Category: 111769-27-8

Synthetic Route of 111769-27-8, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.111769-27-8, Name is (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate, molecular formula is C11H17NO4S. In a Article£¬once mentioned of 111769-27-8

5′-C-ethyl-tetrazolyl-N 6-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists

A series of N6-substituted-5′-C-(2-ethyl-2H-tetrazol-5-yl)-adenosine and 2-chloro-adenosine derivatives was synthesized as novel, highly potent dual acting hA1AR agonists and hA3AR antagonists, potentially useful in the treatment of glaucoma and other diseases. The best affinity and selectivity profiles were achieved by N6-substitution with a 2-fluoro-4-chloro-phenyl-or a methyl-group. Through an in silico receptor-driven approach, the molecular bases of the hA1-and hA3AR recognition and activation of this series of 5′-C-ethyl-tetrazolyl derivatives were explained.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 111769-27-8

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Electric Literature of 111769-27-8, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.111769-27-8, Name is (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate, molecular formula is C11H17NO4S. In a Patent£¬once mentioned of 111769-27-8

NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 111769-27-8

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Synthetic Route of 111769-27-8, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.111769-27-8, Name is (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate, molecular formula is C11H17NO4S. In a Article£¬once mentioned of 111769-27-8

Free-wilson and structural approaches to Co-optimizing human and rodent isoform potency for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors

11beta-Hydroxysteroid dehydrogenase 1 (11beta-HSD1) has been a target of intensive research efforts across the pharmaceutical industry, due to its potential for the treatment of type II diabetes and other elements of the metabolic syndrome. To demonstrate the value of 11beta-HSD1 in preclinical models, we required inhibitors with good potency against both human and rodent isoforms. Herein, we describe our efforts to understand how to co-optimize human and murine potency within the (5-hydroxy-2-adamantyl)-pyrimidine-5-carboxamide series. Two approaches are described-a data-driven (Free-Wilson) analysis and a structure-based design approach. The conclusions from these approaches were used to inform an efficient campaign to design compounds with consistently good human/murine potency within a logD7.4 range of 1-3. Compounds 20 and 26 demonstrated good rodent PK, which allowed us to demonstrate a PK/PD relationship in rat and mouse. We then evaluated 26 against glycemic and body weight end points in murine disease models, where it demonstrated glucose and body weight efficacy at 300 mg/kg/day but only body weight efficacy at 50 mg/kg/day, despite providing >90% target engagement in the liver.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 111769-27-8

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, Recommanded Product: 111769-27-8, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 111769-27-8, Name is (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate, molecular formula is C11H17NO4S

Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826

A compound of formula (I): and pharmaceutically-acceptable salts thereof, wherein the variable groups are defined within; their use in the inhibition of 112HSD1, processes for making them and pharmaceutical compositions comprising them are also described herein.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Recommanded Product: 111769-27-8, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 111769-27-8, in my other articles.

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Chemistry is an experimental science, and the best way to enjoy it and learn about it is performing experiments. Recommanded Product: (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate. Introducing a new discovery about 111769-27-8, Name is (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS

The invention relates to a compound of formula (I) or a salt thereof: wherein:R1 is C1-4alkyl, C1-3fluoroalkyl, -CH2CH2OH or -CH2CH2CO2C1-2alkyl;R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;R3 is optionally substituted C3-8cycloalkyl or optionally substituted mono-unsaturated-C5-7cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n1 and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10; or R3 is a bicyclic group (dd) or (ee):; and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Recommanded Product: (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate, you can also check out more blogs about111769-27-8

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 111769-27-8, molcular formula is C11H17NO4S, introducing its new discovery. 111769-27-8

SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula I wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 111769-27-8, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 111769-27-8

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

111769-27-8, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 111769-27-8, molcular formula is C11H17NO4S, introducing its new discovery.

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as pharmaceuticals.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 111769-27-8, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 111769-27-8

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.111769-27-8,(R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

To a solution of (2,6-dimethylpyridin-4-yl)methyl 4-nitrophenyl carbonate (Intermediate 2;235 mg, 0.78 mmol) in DMF (5 mL) was added DIPEA (400 muL, 2.3 mmol), (R)- tetrahydrofuran-3 -amine toluenesulfonate (221 mg, 0.85 mmol) and DMAP (10 mg, catalytic). The reaction mixture was stirred overnight and then concentrated in vacuo. The residue was dissolved in EtOAc (25 mL), washed with IM aq Na2CO3 solution (5 x 25 mL), dried (MgSO4) and concentrated in vacuo. The residue was dissolved in DCM (5 mL) and treated with 2M HCl in Et2O (0.5 mL, 1.0 mmol) to give a precipitate. The – -solvent was removed by decantation and the precipitate was dried in vacuo to give (2,6- dimethylpyridin-4-yl)methyl (3R)-tetrahydrofuran-3-ylcarbamate hydrochloride (102 mg, 46%) as a white solid.Analytical HPLC: purity 99.3% (System A, Rtau = 3.03 min); Analytical LCMS: purity 100% (System E, Rtau = 4.59 min), ES+: 251.4 [MH]+; HRMS calcd for Ci3Hi8N2O3: 250.1317, found 250.1330.

111769-27-8, The synthetic route of 111769-27-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BIOVITRUM AB (PUBL); WO2009/147216; (2009); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.111769-27-8,(R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

Example 294-((R)-2-{[6-phenyl-(R)-4-(tetrahydro-furan-3-ylamino)-pyridine-2-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester29.1. 4-{3-(ethoxy-hydroxy-phosphoryl)-2-[(6-phenyl-4-pyrrolidin-1-yl-pyridine-2-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid butyl esterA reaction mixture containing intermediate 25.1 (100 mg), (R)-(+)-3-aminotetrahydrofurane to luene-4-sulfonate (43 mg), acetato (2′-di-tert-butylphosphino-1,1′-biphenyl-2-yl)palladium (9.7 mg) and NaOtBu (46 mg) in toluene (1 mL) at 90 C. under argon until reaction completion. The solvent was evaporated in vacuo and the crude product (119 mg) used without further purification.LC-MS: tR=0.78 min; [M+H]+: 632.16., 111769-27-8

111769-27-8 (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate 14243169, aTetrahydrofurans compound, is more and more widely used in various fields.

Reference£º
Patent; Caroff, Eva; Hilpert, Kurt; Hubler, Francis; Meyer, Emmanuel; Renneberg, Dorte; US2011/46089; (2011); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

111769-27-8, (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

l-(5,6-Dichloro-lH-benzo[d]imidazol-2-yl)piperidine-4-carboxylic acid (628 mg, 2.0 mmol), (R)-(+)-tetrahydrofuran-3 -amine 4-methylbenzenesulfonate (622 mg, 2.4 mmol), 2-(7-aza-lH- benzotriazole-l-yl)-l, l,3,3-tetramethyluronium hexafluorophosphate (HATU, 912 mg, 2.4 mmol), N,N-diisopropylethylamine (Hiinig’s base, DIEA, 775 mg, 6.0 mmol) and N,N- dimethylformamide (25 mL) was stirred at room temperature for 100 minutes. The reaction mixure was concentrated in vacuo, the residue purified on column (silica gel, flashchromatography, dichloromethane/methanol, gradient elution 4-20 % methanol) and finally precipitated from chloroform to give 378 mg (49 % yield) of (R)-l-(5,6-dichloro-lH- benzo[d]imidazol-2-yl)-N-(tetrahydrofuran-3-yl)piperidine-4-carboxamide as a white solid. LC- MS (m/z) 382.9 (M+l)., 111769-27-8

As the paragraph descriping shows that 111769-27-8 is playing an increasingly important role.

Reference£º
Patent; NOVASAID AB; WANNBERG, Johan; ALTERMAN, Mathias; MALM, Johan; WO2012/117062; (2012); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem